Pomerantz Law Firm Alerts Investors Regarding Altimmune Class Action Suit and Key Dates

Pomerantz Law Firm's Class Action Notice on Altimmune, Inc.

Pomerantz LLP has issued an important alert for investors who have suffered losses in their investments in Altimmune, Inc. (NASDAQ: ALT). The firm announces that a class action lawsuit has been filed against the company. Investors who wish to participate or seek further information are encouraged to contact Danielle Peyton at Pomerantz via email at [email protected] or by calling 646-581-9980. They can also reach out toll-free at 888.4-POMLAW, extension 7980.

The class action lawsuit focuses on potential securities fraud and other illegal business practices allegedly committed by Altimmune and some of its executives and directors. Investors are advised that they have a deadline until October 6, 2025, to request the court appoint them as Lead Plaintiff if they bought or acquired shares of Altimmune during the defined class period. Interested individuals can obtain a copy of the complaint through the firm's website at www.pomerantzlaw.com.

On June 26, 2025, Altimmune released a press statement outlining the topline results from the IMPACT Phase 2b MASH trial concerning their drug Pemvidutide intended for MASH treatment. Prior to the announcement, Altimmune had raised investor expectations about these results. However, the data revealed a significant lapse, failing to achieve the critical statistical significance regarding the fibrosis reduction endpoint, a central aim of the trial.

Despite observing a positive trend in fibrosis improvement, the results did not meet the statistical benchmarks due to a surprisingly high response rate in the placebo group.

When questioned by analysts about this disappointing outcome, the company’s response was deemed indifferent. They rationalized the results by stating the Phase 2 nature of the trial and maintained optimism for better outcomes in their Phase 3 trials.

Following this revelation, Altimmune's stock suffered a severe setback, plummeting $4.10 per share or 53.2%, leading to a close of $3.61 per share on the same day. This dramatic decline raised dires of concern among investors, catalyzing the class action lawsuit by Pomerantz LLP.

Founded over 85 years ago by the renowned Abraham L. Pomerantz, a trailblazer in securities class actions, Pomerantz LLP has established itself as a leading law firm in areas of corporate, securities, and antitrust litigation. Since its inception, the firm has responsible for multiple settlements resulting in significant damage awards for class members affected by corporate misconduct and securities fraud.

For anyone who believes they have been impacted by these events at Altimmune, now is the critical time for action. The proposed class action represents a collective stance against alleged securities violations, ensuring that the legal rights of affected investors are recognized and pursued.

For further engagement into this matter or to gather more insights regarding joining the class action, please reach out to Pomerantz LLP today. Remember, timely actions before the set deadlines can significantly influence your potential claim outcomes.